Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | ADK | P55263 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18580942 | 1.00 | TSHR (0.48) | TSHRALDH1A1GSK3BADKKDM4E | |
| SCHEMBL18581192 | 1.00 | TSHR (0.48) | TSHRALDH1A1GSK3BADKKDM4E | |
| SCHEMBL18581480 | 0.90 | TSHR (0.47) | TSHRALDH1A1GSK3BADKKDM4E | |
| SCHEMBL29790668 | 0.90 | TSHR (0.47) | TSHRALDH1A1GSK3BADKKDM4E | |
| SCHEMBL18593278 | 0.90 | TSHR (0.47) | TSHRALDH1A1GSK3BADKKDM4E | |
| SCHEMBL18593279 | 0.90 | TSHR (0.47) | TSHRALDH1A1GSK3BADKKDM4E | |
| SCHEMBL29790788 | 0.90 | TSHR (0.47) | TSHRALDH1A1GSK3BADKKDM4E | |
| SCHEMBL20580653 | 0.89 | MEN1 (0.55) | TSHRALDH1A1NPSR1L3MBTL1MEN1 | |
| SCHEMBL18581476 | 0.89 | HDAC6 (0.52) | TSHRALDH1A1HDAC6 | |
| SCHEMBL18581320 | 0.89 | HDAC6 (0.52) | TSHRALDH1A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2018-12-13 | — | — | US | disclosed |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | TSHR 2168/4885ALDH1A1 1338/4885GSK3B 296/4885 |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | TSHR 2168/4885ALDH1A1 1338/4885GSK3B 296/4885 |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | TSHR 2168/4885ALDH1A1 1338/4885GSK3B 296/4885 |
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | TSHR 2168/4885ALDH1A1 1338/4885GSK3B 296/4885 |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | TSHR 2168/4885ALDH1A1 1338/4885GSK3B 296/4885 |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | TSHR 2168/4885ALDH1A1 1338/4885GSK3B 296/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | TSHR 2151/4885ALDH1A1 1573/4885GSK3B 1070/4885 |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | TSHR 2168/4885ALDH1A1 1338/4885GSK3B 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.